Sustained proteolysis is required for human platelet activation by thrombin.

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Thrombin is a key agonist in platelet activation.
• Platelet activation involves complex signaling pathways, including phospholipase C activation and protein kinase activity.
• The role of proteolytic processes in thrombin-mediated platelet signaling is not fully understood.

Purpose of the Study:

• To investigate the effect of indomethacin on thrombin-induced platelet activation.
• To explore the involvement of proteolytic pathways in thrombin signaling in human platelets.
• To determine if protease inhibitors can reverse thrombin-induced platelet activation.

Main Methods:

• Human platelets were stimulated with thrombin in the presence of indomethacin.
• Inositol phospholipid metabolism and protein phosphorylation (including 40,000 and 20,000 dalton proteins) were analyzed.
• The effect of leupeptin, a protease inhibitor, on platelet activation was assessed.

Main Results:

• Indomethacin, even at maximal doses, did not inhibit serotonin release or aggregation.
• Thrombin induced rapid inositol phospholipid degradation and protein kinase C and myosin light chain kinase activation.
• Leupeptin administration reversed thrombin-induced platelet activation when applied post-agonist addition.

Conclusions:

• A maximally effective dose of indomethacin does not prevent thrombin-induced platelet activation.
• Platelet activation by thrombin involves the degradation of inositol phospholipids and protein phosphorylation.
• A proteolytic-mediated pathway appears to be involved in thrombin-induced transmembrane signaling in platelets.